Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2015 | Original Article

Potential diagnostic value of regional myocardial adrenergic imaging using ¹²³I-MIBG SPECT to identify patients with Lewy body diseases

Authors: Adrien Lebasnier, Guillaume Lamotte, Alain Manrique, Damien Peyronnet, Gerard Bouvard, Gilles Defer, Denis Agostini

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2015

Abstract

Purpose

The aim of this study was to determine the potential diagnostic value of regional myocardial adrenergic ¹²³I-metaiodobenzylguanidine (MIBG) single photon emission computed tomography (SPECT) imaging to identify patients with Lewy body diseases (LBD+).

Methods

Sixty-four consecutive patients who underwent cardiac ¹²³I-MIBG SPECT to differentiate LBD+, including Parkinson’s disease (PD) and dementia with Lewy bodies (DLB), from patients without LBD (LBD−) were retrospectively reviewed. A neurologist expert in memory disorders determined the final clinical diagnosis by using international clinical diagnostic criteria. Planar [heart to mediastinum ratio (HMR)] and ¹²³I-MIBG SPECT[(innervation defect score (IDS)] using the 17-segment left ventricular model (five-point scale) were obtained 4 h after the injection of ¹²³I-MIBG on a low-energy high-resolution (LEHR) collimator. Receiver-operating characteristic (ROC) analysis was performed to determine the optimal HMR and IDS cut-off values to discriminate LBD+ from LBD−.

Results

Of the 64 patients, 45 (70 %) were diagnosed LBD+ (DLB, n = 27; PD, n = 18) and 19 were diagnosed LBD− (5 other dementias, 14 other parkinsonisms). The HMR and IDS of LBD+ were significantly different from those of LBD− (1.30 ± 0.21 vs 1.65 ± 0.26, p < 0.001; 39 ± 28 vs 8 ± 16, p = 0.001). The optimal HMR and IDS cut-off values to discriminate LBD+ (n = 45) from LBD− (n = 19) were 1.47 and 6/68, providing a sensitivity and specificity of 82.2 and 84.2 % and 86.7 and 73.7 %, respectively.

Conclusion

Regional myocardial adrenergic ¹²³I-MIBG imaging SPECT has a potential diagnostic value to identify LBD+.

Orimo S, Ozawa E, Nakade S, Sugimoto T, Mizusawa H. (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson’s disease. J Neurol Neurosurg Psychiatry 1999;67:189–94.CrossRefPubMedCentralPubMed

Goldstein DS, Orimo S. Cardiac sympathetic neuroimaging: summary of the First International Symposium. Clin Auton Res 2009;19:137–48.CrossRefPubMedCentralPubMed

King AE, Mintz J, Royall DR. Meta-analysis of 123I-MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord 2011;26:1218–24.CrossRefPubMed

Spiegel J. Diagnostic and pathophysiological impact of myocardial MIBG scintigraphy in Parkinson’s disease. Park Dis 2010;2010:295346.

Flotats A, Carrió I, Agostini D, Le Guludec D, Marcassa C, Schäfers M, et al. Proposal for standardization of 123I-metaiodobenzylguanidine (MIBG) cardiac sympathetic imaging by the EANM Cardiovascular Committee and the European Council of Nuclear Cardiology. Eur J Nucl Med Mol Imaging 2010;37:1802–12.CrossRefPubMed

Stefanelli A, Treglia G, Bruno I, Rufini V, Giordano A. Pharmacological interference with 123I-metaiodobenzylguanidine: a limitation to developing cardiac innervation imaging in clinical practice? Eur Rev Med Pharmacol Sci 2013;17:1326–33.PubMed

Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 2002;105:539–42.CrossRefPubMed

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–4.CrossRefPubMedCentralPubMed

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863–72.CrossRefPubMed

10.

Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71:670–6.CrossRefPubMedCentralPubMed

11.

Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 1996;47:1–9.CrossRefPubMed

12.

Armstrong MJ, Litvan I, Lang AE, Bak TH, Bhatia KP, Borroni B, et al. Criteria for the diagnosis of corticobasal degeneration. Neurology 2013;80:496–503.CrossRefPubMedCentralPubMed

13.

Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP 1998;28:1–126.

14.

Lee PH, Kim JS, Shin DH, Yoon S-N, Huh K. Cardiac 123I-MIBG scintigraphy in patients with drug induced parkinsonism. J Neurol Neurosurg Psychiatry 2006;77:372–4.CrossRefPubMedCentralPubMed

15.

Estorch M, Camacho V, Paredes P, Rivera E, Rodríguez-Revuelto A, Flotats A, et al. Cardiac (123)I-metaiodobenzylguanidine imaging allows early identification of dementia with Lewy bodies during life. Eur J Nucl Med Mol Imaging 2008;35:1636–41.CrossRefPubMed

16.

Quattrone A, Bagnato A, Annesi G, Novellino F, Morgante L, Savettieri G, et al. Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson’s disease. Mov Disord 2008;23:21–7.CrossRefPubMed

17.

Orimo S, Ozawa E, Nakade S, Hattori H, Tsuchiya K, Taki K, et al. [123I] meta-iodobenzylguanidine myocardial scintigraphy differentiates corticobasal degeneration from Parkinson’s disease. Intern Med 2003;42:127–8.CrossRefPubMed

18.

Suzuki M, Kurita A, Hashimoto M, Fukumitsu N, Abo M, Ito Y, et al. Impaired myocardial 123I-metaiodobenzylguanidine uptake in Lewy body disease: comparison between dementia with Lewy bodies and Parkinson’s disease. J Neurol Sci 2006;240:15–9.CrossRefPubMed

19.

Verberne HJ, Feenstra C, de Jong WM, Somsen GA, van Eck-Smit BLF, Busemann Sokole E. Influence of collimator choice and simulated clinical conditions on 123I-MIBG heart/mediastinum ratios: a phantom study. Eur J Nucl Med Mol Imaging 2005;32:1100–7.CrossRefPubMed

20.

Muxí A, Paredes P, Navales I, Valldeoriola F, Gaig C, Lomeña F, et al. Diagnostic cutoff points for 123I-MIBG myocardial scintigraphy in a Caucasian population with Parkinson’s disease. Eur J Nucl Med Mol Imaging 2011;38:1139–46.CrossRefPubMed

21.

Nakajima K, Okuda K, Yoshimura M, Matsuo S, Wakabayashi H, Imanishi Y, et al. Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations. J Nucl Cardiol 2014;21:970–8.CrossRefPubMedCentralPubMed

22.

Courbon F, Brefel-Courbon C, Thalamas C, Alibelli M-J, Berry I, Montastruc J-L, et al. Cardiac MIBG scintigraphy is a sensitive tool for detecting cardiac sympathetic denervation in Parkinson’s disease. Mov Disord 2003;18:890–7.CrossRefPubMed

23.

Geis WP, Kaye MP. Distribution of sympathetic fibers in the left ventricular epicardial plexus of the dog. Circ Res 1968;23:165–70.CrossRefPubMed

24.

Agostini D, Babatasi G, Manrique A, Saloux E, Grollier G, Potier JC, et al. Impairment of cardiac neuronal function in acute myocarditis: iodine-123-MIBG scintigraphy study. J Nucl Med 1998;39:1841–4.PubMed

25.

Estorch M, Carrió I, Berná L, López-Pousa J, Torres G. Myocardial iodine-labeled metaiodobenzylguanidine 123 uptake relates to age. J Nucl Cardiol 1995;2:126–32.PubMed

26.

Treglia G, Cason E, Stefanelli A, Cocciolillo F, Di Giuda D, Fagioli G, et al. MIBG scintigraphy in differential diagnosis of Parkinsonism: a meta-analysis. Clin Auton Res 2012;22:43–55.CrossRefPubMed

27.

Nagayama H, Hamamoto M, Ueda M, Nagashima J, Katayama Y. Reliability of MIBG myocardial scintigraphy in the diagnosis of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2005;76:249–51.CrossRefPubMedCentralPubMed

28.

Nakajima K, Yoshita M, Matsuo S, Taki J, Kinuya S. Iodine-123-MIBG sympathetic imaging in Lewy-body diseases and related movement disorders. Q J Nucl Med Mol Imaging 2008;52:378–87.PubMed

29.

Yoshita M. Differentiation of idiopathic Parkinson’s disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy. J Neurol Sci 1998;155:60–7.CrossRefPubMed

30.

Yates CM, Ritchie IM, Simpson J, Maloney AF, Gordon A. Noradrenaline in Alzheimer-type dementia and Down syndrome. Lancet 1981;2:39–40.CrossRefPubMed

Title: Potential diagnostic value of regional myocardial adrenergic imaging using 123I-MIBG SPECT to identify patients with Lewy body diseases
Authors: Adrien Lebasnier
Guillaume Lamotte
Alain Manrique
Damien Peyronnet
Gerard Bouvard
Gilles Defer
Denis Agostini
Publication date: 01-06-2015
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2015
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-015-2989-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Potential diagnostic value of regional myocardial adrenergic imaging using ¹²³I-MIBG SPECT to identify patients with Lewy body diseases

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2015

Prognostic value of volume-based measurements on 11C-methionine PET in glioma patients

Ursodeoxycholic acid versus phenobarbital pretreatment prior to hepatobiliary scintigraphy in neonatal cholestasis: is it time for shifting gears towards a practice change?

[18F]THK-5117 PET for assessing neurofibrillary pathology in Alzheimer’s disease

11C-PBR28 imaging in multiple sclerosis patients and healthy controls: test-retest reproducibility and focal visualization of active white matter areas

Biodistribution and radiation dosimetry of 82Rb at rest and during peak pharmacological stress in patients referred for myocardial perfusion imaging

Abdelhamid H. Elgazzar: Synopsis of Pathophysiology in Nuclear Medicine